Protalix BioTherapeutics, Inc.
PRX-115
uncontrolled gout
Countdown
542days
Phase 2 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 2 trial results for PRX-115 in uncontrolled gout are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The RELEASE study builds on favorable Phase 1 clinical trial results, where PRX ‑ 115 was generally well-tolerated and demonstrated rapid, durable serum urate reduction below target levels across all cohorts.”